Agile Therapeutics, Inc. (NASDAQ:AGRX) has received an average recommendation of “Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $10.00.

AGRX has been the subject of several analyst reports. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a research note on Wednesday, June 14th. Janney Montgomery Scott reissued a “buy” rating and set a $13.00 target price on shares of Agile Therapeutics in a report on Thursday. HC Wainwright began coverage on Agile Therapeutics in a report on Wednesday, July 19th. They set a “buy” rating and a $10.00 target price for the company. Royal Bank Of Canada set a $8.00 target price on Agile Therapeutics and gave the stock a “buy” rating in a report on Sunday, July 16th. Finally, ValuEngine upgraded Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th.

Shares of Agile Therapeutics (AGRX) traded up 2.36% on Wednesday, reaching $3.47. 526,018 shares of the company were exchanged. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $7.95. The stock’s market capitalization is $99.96 million. The stock has a 50 day moving average price of $3.74 and a 200-day moving average price of $3.40.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.02. During the same quarter in the prior year, the firm earned ($0.29) EPS. On average, equities analysts expect that Agile Therapeutics will post ($1.03) EPS for the current fiscal year.

In other news, Chairman Alfred Altomari bought 10,000 shares of the stock in a transaction dated Friday, August 25th. The shares were bought at an average cost of $3.34 per share, with a total value of $33,400.00. Following the completion of the transaction, the chairman now directly owns 161,587 shares of the company’s stock, valued at $539,700.58. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.50% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP bought a new position in Agile Therapeutics in the 2nd quarter valued at $205,000. Royal Bank of Canada lifted its position in shares of Agile Therapeutics by 608.0% during the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 27,907 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Agile Therapeutics during the 2nd quarter valued at $309,000. Dimensional Fund Advisors LP lifted its position in shares of Agile Therapeutics by 604.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after buying an additional 82,213 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Agile Therapeutics by 39.2% during the 2nd quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after buying an additional 780,578 shares during the last quarter. Institutional investors and hedge funds own 67.59% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Analysts Set Agile Therapeutics, Inc. (AGRX) Target Price at $10.00” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/09/analysts-set-agile-therapeutics-inc-agrx-target-price-at-10-00.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.